Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Summary
The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.
Arms & interventions
Outcome measures
Primary
Assess real world progression-free survival in patients with locally advanced or metastatic NSCLC treated with first line osimertinib
Time frame: From the index date (date of initiation of first line treatment for metastatic disease) until date of progression or date of death whichever comes first, assessed up to 100 months)
Secondary
Assess overall survival in patients with locally advanced or metastatic NSCLC treated with first line osimertinib
Time frame: From the index date (date of initiation of first line treatment for metastatic disease) until death, as assessed up to 100 months
Assess time to treatment discontinuation in patients with locally advanced or metastatic NSCLC treated with first line osimertinib
Time frame: From the index date (date of initiation of first line treatment for metastatic disease) until treatment discontinuation, as assessed up to 100 months
Eligibility criteria
Study locations (8)
Pacific Cancer Care
Monterey, California, 93940
Torrance Memorial Physician Network-Cancer Care
Torrance, California, 90505
Bayhealth Cancer Center- Kent
Dover, Delaware, 19901
Bayhealth Cancer Center- Sussex
Milford, Delaware, 19963
Kootenai Clinic Cancer Services Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Northwest Oncology & Hematology
Elk Grove Village, Illinois, 60007
Lankenau Medical Center
Paoli, Pennsylvania, 19301
Oncology Consultants, P.A.
Houston, Texas, 77030